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Abstract
Introduction Hemophagocytic syndrome represents a
severe hyperinflammatory condition by activated macro-
phages. Leading viral triggering agents are Epstein-Barr
virus (EBV), cytomegalovirus (CMV), and adenovirus.
Materials and methods We present a patient with Wegen-
er’s granulomatosis on azathioprine and prednisone medica-
tion, who developed a life-threatening hemophagocytic
syndrome. Positive plasma polymerase chain reaction (PCR)
with negative serology revealed a primary, disseminated
infection with herpes simplex virus-1 as the triggering path-
ogen. After treatment with acyclovir, high-dose steroids,
immunoglobulins, and etoposide, the patient recovered.
Conclusion Early diagnosis of potentially underlying
infections of hemophagocytic syndrome influences the
therapeutic approach. It is important to consider a variety of
infectious agents, particularly in immunosuppressed indi-
viduals. The reported case emphasizes the importance of
screening for herpes simplex virus 1.
Keywords Hemophagocytic syndrome  Primary herpes
simplex infection  Immunosuppression  Wegener’s
granulomatosis
Introduction
Hemophagocytic syndrome represents a severe hyperin-
flammatory condition characterized by prolonged fever,
cytopenia, hepatosplenomegaly, and hemophagocytosis
by activated macrophages. The acquired hemophagocy-
tic syndrome was first described in 1979 by Risdall
et al. [1] in association with viral infections following
organ transplantation. Subsequently, it became clear
that, also, non-viral pathogens, including bacteria, pro-
tozoae, and fungi, can trigger hemophagocytic syndrome
[2]. Leading viral triggering agents are Epstein–Barr
virus (EBV), cytomegalovirus (CMV), and adenovirus.
To the best of our knowledge, we present here the first
case of a hemophagocytic syndrome in an adult caused
by a primary infection with herpes simplex virus type 1
(HSV-1).
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Case
The 57-year-old patient was diagnosed with c-ANCA-
associated Wegener’s granulomatosis in 1999. Progressive
glomerulonephritis resulted in renal failure requiring dial-
ysis 8 years later. In July 2008, the patient developed
progressive malaise with elevated inflammation markers
(Table 1) and recurrent fevers. Since a relapse of Wegen-
er’s granulomatosis was suspected, prednisone was aug-
mented from 10 to 50 mg/daily, while azathioprine was
maintained at 150 mg/daily. Despite the increased immu-
nosuppressive therapy, the patient’s clinical condition
deteriorated rapidly, making a relapse of the Wegener’s
granulomatosis unlikely. The patient developed right-sided
abdominal pain and the computed tomography (CT) scan
was suspicious for cholecystitis. Since empiric antibiotic
treatment was not successful, cholecystectomy was per-
formed 2 weeks later, showing chronic cholecystitis.
After surgery, fever persisted and the patient developed
severe pancytopenia. Consequently, immunosuppression
with azathioprine was stopped and the patient was referred
to our hospital for further investigations. The patient
required mechanical ventilation because of reduced con-
sciousness. Laboratory examinations on admission showed
severe pancytopenia (Table 1) and highly elevated values
for ferritin, soluble IL-2 receptor, and neopterin, raising the
suspicion for hemophagocytic syndrome. Bone marrow
examinations showed marked hypocellularity and an
increase of macrophages with hemophagocytosis (Fig. 1).
Microbiological investigations showed no evidence for
infection with CMV, EBV, human parvovirus B19, hepa-
titis A, B, C, and HIV. Blood and stool cultures remained
negative. A highly positive DNA polymerase chain reac-
tion (PCR) for HSV-1 was found in the peripheral blood
with 157 million genome copies/mL. The only clinical sign
for a HSV-1 infection was a vesicular eruption on the
buccal mucosa, where HSV-1 DNA could be detected as
well. The PCR was done according to the primer sequences
published by Pevenstein et al. [3] using a Taqman MGB
probe with the Applied Biosystems 7300 real-time PCR
system. IgM and IgG serology for HSV was negative on
admission, being compatible with a primary HSV-1
infection. Treatment with acyclovir was initiated. HSV was
also found in the cerebrospinal fluid (CSF, 6,000 genome
copies/mL). However, CSF revealed normal cell count
(1 cell/lL), protein, and glucose levels. Neither magnetic
resonance imaging (MRI) nor electroencephalography
showed typical signs of HSV-encephalitis. The detection of
HSV-1 genome in the CSF being 5log lower than in the
plasma was interpreted as a spillover from plasma rather
than as intracerebral HSV-1 replication.
Treatment for hemophagocytic syndrome was initiated
with 2,500 mg methylprednisolone daily for 3 days, fol-
lowed by three further doses of 100 mg prednisone daily.
Table 1 Laboratory values
17 days prior
to admission
Admission Discharge
from ICU
Discharge
from hospital
Follow-up 5 weeks
after hospital
discharge
Follow-up
after 1 year
Hemoglobin, g/L (normal range 14.0–18.0) 12.1 7.6 7.4 8.4 11 12.5
Leucocyte count, 109/L (normal range 3.5–10.0) 4.0 0.85 14.2 3.5 6.1 6.1
Platelet count, 109/L (normal range 145–400) 155 14 54 133 188 150
C-reactive protein, mg/L (normal range \5) 109 334 151 17 13 2
Ferritin, lL/L (normal range 10–400) – 174,000 6,641 3,569 1,616 823
Soluble IL-2 receptor, U/mL (normal range\800) – 14,315 4,973 – – –
Neopterin, ng/mL (normal range \2.5) – 538 100 38.9 26.5 –
Herpes simplex virus type 1 viral load
(DNA copies/mL of plasma)
– 157 million 30,000 Not detectable Not detectable Not detectable
Herpes simplex virus IgG Negative Negative Positive Positive – Positive
Fig. 1 Bone marrow examination revealed a reduction of the
cellularity in all lineages. Macrophages were increased with signs
of hemophagocytosis. The white arrow shows erythrocytes within the
cytoplasm of a macrophage
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Due to insufficient response to the steroids, etoposide
(100 mg loading dose, consecutively reduced to 20 mg/
day) and intravenous immunoglobulins (40 g for 3 days)
were added to the therapy.
Although the activity markers of the hemophagocytic
syndrome declined rapidly during the first days of treatment,
they did not reach normal levels. Likewise, severe pancy-
topenia persisted, requiring regular substitution of erythro-
cytes and platelets. After 4 weeks, the patient’s condition
slowly improved, and he was weaned off the ventilator.
Acyclovir was given for 8 weeks and resulted in a complete
suppression of HSV in plasma. Nine weeks after admission,
the patient still presented signs of severe encephalopathy
and bone marrow biopsy showed ongoing, although less
intense, signs of hemophagocytosis. Thus, another course of
high-dose steroids and intravenous immunoglobulins was
administered. Thereafter, the patient’s neurological status
improved considerably and in the subsequent bone marrow
microscopy, a distinct improvement of the hemophagocytic
activity was documented. Repeated HSV serology revealed
a seroconversion. The patient was discharged from hospital
after 13 weeks and he remained in good clinical condition
since. One year later, he underwent successful kidney
transplantation.
Discussion
To the best of our knowledge, we report here the first case
in which hemophagocytic syndrome was caused by a pri-
mary HSV-1 infection unambiguously documented by a
seroconversion in the course of the disease. So far, only six
adults with hemophagocytic syndromes associated with
HSV infections are described in the literature. One case
was associated with HSV-1 as diagnosed by increasing
antibody titer, suggesting HSV-1 reactivation [4]. Three
cases had HSV-2 [5–7] and in two cases, the virus subtype
was not specified [1, 8]. Several factors may account for
the rarity of a primary HSV-1 infection as a cause of hemo-
phagocytic syndrome. First, it is unusual that a 57-year-old
patient has a negative HSV-1 serology. The prevalence of
HSV-1 infection increases gradually with age; by the fifth
decade of life, positive HSV-1 antibodies can be found in
up to 90% of the population [9]. Thus, during adulthood,
the reactivation of HSV-1 is more frequent than primary
infection.
Second, primary HSV-1 infections are generally asso-
ciated with local mucocutaneous vesicular eruptions only.
Dissemination of HSV occurs almost only in association
with an underlying primary immune deficiency or secon-
dary to immunosuppressive treatment. Disseminated
infections can present with or without visible mucocuta-
neous lesions and may include sites that are rarely involved
in an immunocompetent host, such as the lungs or the
gastrointestinal tract. In virus-associated hemophagocytic
syndrome, it is thought that the infection provokes an
abnormal immune response, resulting in the secretion of
cytokines, including c-Interferon, IL18, and macrophage
colony stimulating factor, by T-helper and dysfunctional
cytotoxic T- and natural killer-cells. This results in massive
macrophage activation with an associated macrophage-
derived cytokine storm and phagocytosis of both erythro-
cytes and white blood cells [2, 10]. It is difficult to estimate
if the inadequate immunologic response in our patient was
a consequence of the pre-existing immune dysfunction
(Wegener’s granulomatosis) or a result of the long-term
immunosuppressive therapies.
Hemophagocytic syndrome may be difficult to distin-
guish from severe sepsis. Autopsy studies suggest that
hemophagocytic syndrome may be underdiagnosed in
intensive care patients [11]. It should be considered rou-
tinely in patients with unexplained multiple organ failure
[12]. Diagnosis can be established when five of the eight
following criteria are fulfilled: fever, splenomegaly, cyto-
penia of at least two cell lines, hypertriglyceridemia and/or
hypofibrinogenemia, increased ferritin, increased soluble IL-2
receptor, decreased or absent natural killer-cell activity,
hemophagocytosis in bone marrow, CSF, or lymph nodes
[13].
The appropriate diagnostic approach to patients with
suspected hemophagocytosis syndrome is not well defined.
Potentially treatable causes of hemophagocytosis syndrome
should be sought. Fisman [2] suggests that all patients with
suspected infection-associated hemophagocytic syndrome
should undergo extensive testing for underlying infections
guided by epidemiological data and medical history. Chest
radiography or CT scans, blood and urine cultures,
screening for EBV, CMV and parvovirus B19, HIV, and
human herpes virus 6, either through serologic testing or
PCR should be performed. Additionally, fungal infections
should be considered. Patients with a travel history should
be screened for leishmaniasis, brucellosis, rickettsioses,
and malaria. HSV screening has not been incorporated into
guidelines yet. However, since it represents a treatable
underlying cause, we recommend screening for HSV in all
patients and, in particular, in immunosuppressed ones. As
shown in this case report, HSV serology is not sufficient to
rule out hemophagocytic syndrome caused by primary
HSV-1 infection. Such cases are only detectable by posi-
tive PCR.
The therapy of infection-associated hemophagocytic
syndrome has to weigh the benefit of attenuating excessive
macrophage activity against the potential risk of an infec-
tion flare. The aim is to suppress the severe hyperinflam-
mation responsible for the life-threatening symptoms. On
the other hand, the pathogen must be eradicated, hence,
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removing the stimulus for the ongoing activation of T-cells.
Pathogen control is usually not sufficient to control hyper-
inflammation. This was also demonstrated in our case; even if
HSV-1 could be successfully suppressed in plasma by the use
of acyclovir, the patient needed a second anti-inflammatory
treatment with methylprednisolone to recover from the he-
mophagocytic syndrome. In patients with less severe symp-
toms, corticosteroids and immunoglobulins may be sufficient
to control the excessive inflammation. However, if symptoms
progress, the use of dexamethasone, etoposide, or cyclospor-
ine A can be considered. In EBV-associated hemophagocytic
syndrome for instance, etoposide has been shown to be
effective [14].
In summary, hemophagocytic syndrome is a life-
threatening condition, which may be difficult to diagnose.
The reported case emphasizes the importance of an accu-
rate diagnosis of potentially underlying infections because
it influences the therapeutic approach. It is important to
consider a variety of infectious agents, particularly in
immunosuppressed individuals. We recommend to screen
broadly for herpes viruses by serology and, perhaps even
more importantly, by plasma DNA PCR.
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